Which antihypertensive drugs should be used in the primary prevention of cardiovascular disease?;Hvilke blodtrykkssenkende legemidler bør brukes for primærforebygging av hjerte- og karsykdommer?

Tidsskrift for den Norske Laegeforening

Volumn 122, Issue 23, 2002, Pages 2283-2286

  Fretheim, Atle ^a   Bjørndal, Arild ^a   Oxman, Andrew D ^a   Dyrdal, Audun ^a   Golding, Michael ^a   Ose, Leiv ^a   Reikvam, Åsmund ^a   Teisberg, Per ^a  

^a Sosial og Helsedirektoratet ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG INDICATION; GOUT; HYPERCHOLESTEROLEMIA; HYPERTENSION; MICROALBUMINURIA; PRACTICE GUIDELINE; CORONARY RISK; HIGH RISK PATIENT; HUMAN;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; NORWAY; PRACTICE GUIDELINES; PRIMARY PREVENTION; ANTICHOLESTEREMIC AGENTS; HYPERCHOLESTEROLEMIA;

EID: 0037201479     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L et al. Retningslinjer for medikamentell primærforebygging av hjerte- og karsykdommer - Hvem bør behandles? Tidsskr Nor Lægeforen 2002; 122: 2277-81.
2. Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L et al. Hvilke kolesterolsenkende legemidler bør brukes for primærforebygging av hjerte- og karsykdommer? Tidsskr Nor Lægeforen 2002; 122: 2287-8.
3. Wright JM, Lee C, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a firstline drug? Can Med Assoc J 1999; 161: 25-32.
4. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739-45.
5. Lindholm LH, Agenäs I, Dahlgren H, de Faire U, Goodman C, Hjemdahl P et al. Moderately elevated blood pressure. A report from SBU, The Swedish council on technology assessment in health care. J Intern Med 1995; 238: S1-S225.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
7. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
8. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-72.
9. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283: 1967-75.
11. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. Single-drug therapy for hypertension in men. N Engl J Med 1993; 328: 914-21.
12. Neaton JD, Grimm RH Jr., Prineas RJ, Stamler J, Grandits GA, Elmer PJ et al. Treatment of mild hypertension study. JAMA 1993; 270: 713-24.
13. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Reults of the HANE study. BMJ 1997; 315: 159.
14. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
15. Therapeutics Initiative. Drugs of Choice in the Treatment of Hypertension, Therapeutics Letters 7, 8 & 16. Vancouver: Therapeutics Initiative, 1995.
16. Claudi T, Cooper JG, Midthjell K, Daae C, Furuseth K, Hanssen KF. NSAMs Handlingsprogram for Diabetes i Allmennpraksis. Skriftserie for Leger: Kvalitetssikring i Diabetsomsorgen. Oslo: Norsk selskap for allmennmedisin, Den norske lægeforening, Norges diabetesforbund, Folkehelsa, 2000.
17. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers G et al. 1999 Canadian recommendations for the management of hypertension. Can Med Assoc J 1999; 161: S1-S16.
18. Kjeldsen SE, Os I, Farsang C, Mallion J-M, Hansson L, Sleight P. Treatment of hypertension in patients with type-2 diabetes mellitus. Blood Press 2000; 9: 363-4.
19. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria (Cochrane Review). I: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
20. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 1995; 10: 39-45.
21. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
23. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
24. Fuller J, Stevens LK, Chaturverdi N, Holloway JF. Antihypertensive therapy in diabetes mellitus (Cochrane Review). I: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
25. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
26. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283: 3177-9.
27. Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly (Cochrane Review). I: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
28. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
29. Weir MW, Moser M. Diuretics and betablockers: Is there a risk for dyslipidemia? Am Heart J 2000; 139: 174-83.
30. Chafin CC, Soberman JE, Demirkan K, Self T. Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma? Cardiology 1999; 92: 99-105.
31. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease (Cochrane Review). I: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.
32. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2: 539-43.
33. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989; 3: 457-61.
34. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
35. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfuncion: A systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
36. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
37. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-91.
38. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
39. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, Dejong PE. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.
40. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-45.
41. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
42. Wood D, De Backer G, Færgeman O, Graham I, Mancia G, Pyörälä K. Forebyggelse av Koronar Hjertesykdom i Klinisk Praksis. Oslo: Norsk Cardiologisk Selskap, 2000.
43. Meland E, Ellekjær H, Gjelsvik B, Kimsås A, Holmen J, Hetlevik I. Medikamentell forebygging av hjerte- og karsykdommer i allmennpraksis. Tidsskr Nor Lægeforen 2000; 120: 2643-7.